Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.85
-1.6%
$6.92
$4.58
$9.66
$400.10M1.89455,408 shs665,310 shs
Humacyte, Inc. stock logo
HUMA
Humacyte
$2.53
-5.2%
$2.42
$1.15
$9.79
$414.17M1.893.94 million shs4.16 million shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$23.08
+0.0%
$16.58
$10.80
$24.75
$333.96M-0.04142,922 shs193,206 shs
OncoCyte Corporation stock logo
OCX
OncoCyte
$3.18
+16.3%
$3.07
$1.92
$4.75
$90.80M0.9758,260 shs100,514 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
-1.63%+9.18%+9.94%+36.28%-8.51%
Humacyte, Inc. stock logo
HUMA
Humacyte
-5.24%+8.58%+15.53%+75.69%-68.61%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
+0.04%-5.60%+54.80%+88.25%+71.60%
OncoCyte Corporation stock logo
OCX
OncoCyte
0.00%0.00%0.00%-7.70%-1.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CryoPort, Inc. stock logo
CYRX
CryoPort
1.7787 of 5 stars
3.41.00.00.02.22.50.0
Humacyte, Inc. stock logo
HUMA
Humacyte
1.6511 of 5 stars
3.51.00.00.01.70.80.6
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
3.0857 of 5 stars
0.03.00.04.63.62.51.3
OncoCyte Corporation stock logo
OCX
OncoCyte
1.2317 of 5 stars
3.40.00.00.00.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CryoPort, Inc. stock logo
CYRX
CryoPort
2.78
Moderate Buy$11.1141.54% Upside
Humacyte, Inc. stock logo
HUMA
Humacyte
3.00
Buy$11.71363.02% Upside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.00
HoldN/AN/A
OncoCyte Corporation stock logo
OCX
OncoCyte
2.75
Moderate Buy$6.0690.94% Upside

Current Analyst Ratings Breakdown

Latest OCX, HUMA, CYRX, and INBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/23/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
7/22/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$13.00
7/9/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
7/7/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $10.00
6/9/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
5/21/2025
OncoCyte Corporation stock logo
OCX
OncoCyte
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
5/21/2025
OncoCyte Corporation stock logo
OCX
OncoCyte
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.00 ➝ $8.00
5/15/2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/14/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$4.00
5/14/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $14.00
5/13/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.72N/AN/A$7.44 per share1.06
Humacyte, Inc. stock logo
HUMA
Humacyte
$1.57M249.97N/AN/A($0.41) per share-6.17
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$200K1,670.53$115.40 per share0.20$9.23 per share2.50
OncoCyte Corporation stock logo
OCX
OncoCyte
$3.84M23.63N/AN/A($0.70) per share-4.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
Humacyte, Inc. stock logo
HUMA
Humacyte
-$148.70M-$0.69N/AN/AN/AN/AN/A-73.59%8/12/2025 (Estimated)
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.69B$116.750.20N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)
OncoCyte Corporation stock logo
OCX
OncoCyte
-$60.66M-$3.53N/AN/AN/A-1,516.06%-215.59%-27.23%8/6/2025 (Estimated)

Latest OCX, HUMA, CYRX, and INBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Humacyte, Inc. stock logo
HUMA
Humacyte
-$0.15N/AN/AN/A$0.94 millionN/A
8/12/2025Q2 2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.92N/AN/AN/AN/AN/A
8/6/2025Q2 2025
OncoCyte Corporation stock logo
OCX
OncoCyte
-$0.24N/AN/AN/A$0.29 millionN/A
8/5/2025Q2 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20N/AN/AN/A$41.74 millionN/A
5/14/2025Q4 2024
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.55-$2.80-$0.25-$2.80N/AN/A
5/13/2025Q1 2025
Humacyte, Inc. stock logo
HUMA
Humacyte
-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million
5/12/2025Q1 2025
OncoCyte Corporation stock logo
OCX
OncoCyte
-$0.24-$0.26-$0.02-$0.26$0.13 million$2.14 million
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Humacyte, Inc. stock logo
HUMA
Humacyte
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
OncoCyte Corporation stock logo
OCX
OncoCyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
Humacyte, Inc. stock logo
HUMA
Humacyte
0.36
3.68
3.28
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.04
5.12
5.12
OncoCyte Corporation stock logo
OCX
OncoCyte
0.20
3.74
3.70

Institutional Ownership

CompanyInstitutional Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Humacyte, Inc. stock logo
HUMA
Humacyte
44.71%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%
OncoCyte Corporation stock logo
OCX
OncoCyte
55.35%

Insider Ownership

CompanyInsider Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Humacyte, Inc. stock logo
HUMA
Humacyte
5.10%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
17.09%
OncoCyte Corporation stock logo
OCX
OncoCyte
2.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.12 millionOptionable
Humacyte, Inc. stock logo
HUMA
Humacyte
150155.12 million147.21 millionOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.48 million12.00 millionOptionable
OncoCyte Corporation stock logo
OCX
OncoCyte
12028.60 million28.01 millionNo Data

Recent News About These Companies

OncoCyte (NASDAQ:OCX) Shares Up 16.3% - Still a Buy?
Oncocyte Reports Q1 2025 Results and Business Progress
OncoCyte Q1 2025 Earnings Preview
Best Momentum Stocks to Buy for May 6th
New Strong Buy Stocks for May 6th

New MarketBeat Followers Over Time

Media Sentiment Over Time

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.85 -0.13 (-1.63%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$7.85 0.00 (0.00%)
As of 07/25/2025 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Humacyte stock logo

Humacyte NASDAQ:HUMA

$2.53 -0.14 (-5.24%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$2.56 +0.03 (+0.99%)
As of 07/25/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$23.08 +0.01 (+0.04%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$23.12 +0.04 (+0.15%)
As of 07/25/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

OncoCyte stock logo

OncoCyte NASDAQ:OCX

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.